

In the Claims:

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1. (Previously presented) A method of expressing a gene product in the gut of an animal, which comprises:
administering an encapsidated recombinant AAV vector to the gut of said animal, wherein said vector comprises a non-AAV gene of interest operably linked to a promoter operable in gut.
2. (Previously presented) The method of Claim 1, wherein said vector is administered with a liquid pharmaceutically acceptable carrier.
3. (Original) The method of Claim 1, wherein said liquid carrier comprises an aqueous solution.
4. (Currently amended) The method of Claim 1, wherein said vector is administered in a solid pharmaceutically acceptable carrier.
5. (Previously presented) The method of Claim 1, wherein said gene of interest comprises a DNA segment encoding a protein operably linked to said promoter operable in gut.
6. (Original) The method of Claim 1, wherein said administering is by oral ingestion.
7. (Cancelled)

8. (Currently amended) The method of Claim 1, wherein said AAV vector either comprises non-AAV DNA ligated into an AAV genome in place of or in addition to an AAV DNA sequence excluding the first and last 145 basepairs of said AAV genome or comprises non-AAV DNA operably linked to a vector comprising a double-D AAV genomic segment consisting of 165 basepairs including an internal terminal repeat with D segments at both ends.

9. (Cancelled)

10. (Original) The method of Claim 1, wherein said animal is a bird or mammal.

11. (Original) The method of Claim 1, wherein said animal is a human.

12. (Currently amended) The method of claim 1, wherein said non-AAV gene of interest comprises a β -galactosidase gene operatively linked to a the promoter.

In the Drawings:

Please replace Figures 1A-1C and Figures 2A-2B previously submitted with the accompanying new formal drawings.